# AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

> **NCT00321724** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (estimated)

## Conditions studied

- B-cell Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** cediranib maleate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00321724
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-05
- **Final completion:** —
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2013-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00321724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00321724, "AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00321724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*